Healthcare Professionals – e-Learning

Learning Objectives:

• Recall updates to National Advisory Committee on Immunization (NACI) recommendations for influenza vaccination and expected changes to vaccine composition
• Describe the role of real-world evidence in clinical decision making
• Explain the association between influenza infection and cardiovascular events, loss of functional independence, and frailty in older adults
• Counsel older adults on the impact of vaccination on reducing the above risks and vaccine options indicated for this population

This continuing education is free for members of CanadianHealthcareNetwork.ca. Visit www.canadianhealthcarenetwork.ca to sign up.

Visit eCortex.ca to register.

Learning Objectives:

At the end of this on-demand webinar, you will be able to:

• Describe the burden of RSV disease in the adult population and risk as related to age and underlying medical conditions Identify risk factors for severe complications of RSV and why older adults face a higher risk
• Understand new clinical evidence supporting RSV vaccination and current vaccine technologies to address age-related decline in immunity
• Apply best practices and tools for identifying adults at risk of serious outcomes from RSV in your practice
• Acquire strategies for implementing RSV vaccination into practice to optimize adult immunization

This continuing education is free for members of CanadianHealthcareNetwork.ca. Visit www.canadianhealthcarenetwork.ca to sign up.

Visit eCortex.ca to register.

This training module is intended as a refresher on how to administer the flu vaccine. The module can be completed within 30 minutes.

The iMD Patient Engagement Platform is a web-based patient education platform that is available on any device with internet. iMD Health enables healthcare providers to bring their patient sessions to life through the seamless integration of professionally-vetted diagrams, educational resources, brochures and videos covering over 1,800 medical conditions, procedures and treatment options.

To get your account, visit app.imdhealth.com/signup.

Target Audience and Goal Statement

This educational activity is intended for Europe and Canada-based pediatricians, pulmonologists, primary care practitioners, nurses, and pharmacists.

The goal of this activity is for learners to be better able to understand the burden of influenza in children and how children are key factors in influenza transmission in the community.

Upon completion of this activity, participants will:

• Have increased knowledge regarding the Burden of influenza in children
• Influenza transmission dynamics in children and to others

Visit Medscape to register.

This is a 30-minute CFPC Mainpro+ certified eCME program for Canadian HCPs. The goal is to provide education on the burden of influenza in older adults, and the clinical data used to support vaccination options for this high-risk population. This program is designed to provide practical information on available influenza vaccines in Canada, concurrent administration with other vaccines and national recommendations in order to support clinicians with discussions on optimal protection for older adults.

Learning Objectives

Upon completion of this continuing education program participants will be better able to:

• Describe the burden of influenza in older adults and the importance of influenza vaccination
• Evaluate the evidence pertaining to influenza vaccines in older adults
• Apply NACI 2024-2025 recommendations for influenza vaccination and concurrent administration with other vaccines in older adults

Visit mdBriefCase to register.

This is a 30-minute CCCEP certified eCME program for Canadian pharmacists. The goal is to provide education on the burden of influenza, and influenza prevention and control measures, with a focus on older adults, and the clinical data used to support vaccination options for this high-risk population. This program is designed to provide practical information on the available influenza vaccines in Canada, and national recommendations in order to support discussions with older adults on the optimal protection available to them.

Learning Objectives

Upon completion of this continuing education program participants will be better able to:

• Describe the burden of influenza in older adults and the importance of influenza vaccination
• Apply NACI 2024-2025 recommendations for influenza vaccination and concurrent administration with other vaccines in older adults
• Implement influenza vaccination in clinical practice

Visit mdBriefCase to register.

This is a 15-minute expert brief for Canadian primary care providers and other healthcare professionals. Due to the limited therapeutic options available to manage RSV disease, the goal is to provide education on disease prevention. This expert brief is designed to provide practical information on passive immunization options available for infants in Canada, with a focus on NACI’s recommendations for the use of nirsevimab, the recently authorized long-acting monoclonal antibody. The expert brief video will feature a conversation between a Pediatric Infectious Disease Specialist and a Family Physician.

Learning objectives:
After viewing this expert brief, participants will be better able to:

• Recognize the burden of RSV disease in all infants
• Summarize NACI guidance for a universal RSV immunization program
• Implement RSV immunoprophylaxis in clinical practice

Visit mdBriefCase to register.

This 60-minute webinar is designed to provide Canadian HCPs with practical information on passive immunization options available in Canada, with a focus on the newly authorized long-acting monoclonal antibody nirsevimab, and the maternal RSVpref vaccine. The webinar will discuss RSV prevention through case studies, and highlight how a hospital order set can support implementation of the new RSV immunoprophylaxis in clinical practice.

Learning objectives:
Upon completion of this program, participants will be able to:

• Describe the prevalence and burden of RSV disease in all infants
• Summarize NACI guidance and supporting evidence on passive immunization for RSV
• Implement a hospital order set for RSV prevention to support clinical practice

Visit mdBriefCase to register.

Target Audience and Goal Statement

The intended audience for this activity is obstetricians/gynecologists, nurse practitioners, and other healthcare professionals involved in the management of expectant parents.

Respiratory syncytial virus (RSV) is the most common cause of bronchiolitis and pneumonia in infants in the United States. Infants and certain young children are at higher risk for severe illness, especially in the setting of premature birth, immune compromise, or comorbid conditions. Recently, new preventive options have become available, including a maternal RSV vaccine for expectant mothers and a long-acting immunoprophylactic agent for infants and certain young children. Education is needed to keep clinicians up to date on the latest evidence-based recommendations for RSV prevention. This CME activity provides education on the burden of RSV disease in infants and evaluates passive immunization approaches. Experts in obstetrics, maternal-fetal medicine, and pediatric infectious disease will discuss effective comprehensive, interprofessional strategies to help prevent RSV transmission and severe illness among newborns.

Upon completion of this activity, participants will:

• Review the significant patient, parent, and healthcare burden associated with infant and young child RSV infections and alterations in RSV season trends.
• Characterize approved monoclonal antibodies for RSV prevention in infants and young children by pharmacology, dosing, administration, and recent safety and efficacy data.
• Discuss interprofessional strategies to prevent and mitigate RSV infections in infants and young children, including evidence-based recommendations.

Visit Medscape to register.

This is a 60-minute eCME for Canadian HCPs. Due to the significant burden of disease of RSV in infants and young children, the goal is to provide education on the role of RSV immunoprophylaxis in disease prevention. This program is designed to provide practical information on recently authorized RSV immunoprophylaxis available in Canada, with a focus on nirsevimab, a long-acting monoclonal antibody. Utilizing case studies and expert videos, the program will review the burden of RSV disease in infants, supporting evidence for recently approved RSV immunoprophylaxis, NACI guidance for RSV immunoprophylaxis for all infants and considerations for the use of nirsevimab in clinical practice.

Learning objectives:
Upon completion of this continuing education program participants will be better able to:

• Cite the prevalence and burden of RSV disease in infants
• Evaluate clinical and safety data of recently approved RSV immunoprophylaxis for infants
• Summarize NACI guidance on RSV immunoprophylaxis for all infants
• Implement RSV immunoprophylaxis for infants in clinical practice

Visit mdBriefCase to register.

Target Audience and Goal Statement

This activity is intended for primary care physicians and infectious disease specialists.

The goal of this activity is for learners to be better able to understand the etiology and impact of Chikungunya virus (CHIKV), how climate change is affecting its distribution, challenges with diagnosis and management, and recent clinical data on the CHIKV vaccines.

Upon completion of this activity, participants will:

• Have increased knowledge regarding the
  • Impact that climate change has on CHIKV transmission and epidemiology
  • Current clinical challenges in diagnosing CHIKV
  • Status of CHIKV vaccine development

Visit Medscape to register.

This is a 45-minute, CFPC/CCCEP/OPQ-accredited eCME program for primary care physicians, pharmacists and other travel health practitioners. The goal is to equip healthcare providers with knowledge about the mosquito-borne chikungunya virus, including transmission, risk factors, diagnostic criteria and disease management, while also unveiling new preventative strategies, including vaccines in development, to protect against the chikungunya virus.

Learning objectives:
Upon completion of this continuing education program, participants will be better able to:

• Explain the epidemiology and burden of chikungunya virus
• Describe the clinical presentation and morbidity of chikungunya virus infection
• Counsel travellers on preventative strategies to reduce mosquito-borne viral infections
• Describe the chikungunya vaccines under development and the potential role of vaccination in preventing chikungunya virus infection

Visit mdBriefCase to register.

Chikungunya virus (CHIKV), a mosquito-borne alphavirus, is the causative agent of chikungunya (CHIK) disease, a condition with low mortality but high acute and chronic morbidity resulting in high overall burden of disease. Infection rates of CHIKV have increased in recent years, and this upward trend is expected to continue as vector habitats continue to expand. This program will provide participants with key insights into CHIKV, including its epidemiology, clinical manifestations, diagnosis, current management and preventative strategies, including vaccines in development. The objective is to enable participants to enhance their knowledge of the disease and diagnostic skills, implement effective management strategies and contribute to public health efforts to protect against the virus.

This program has received an educational grant or in-kind support from Valneva.

Learning objectives:
Upon completion of this continuing education program, participants will be better able to:

• Explain the epidemiology and burden of chikungunya virus
• Describe the clinical presentation and morbidity of chikungunya virus infection
• Counsel travellers on preventative strategies to reduce mosquito-borne viral infections
• Describe he chikungunya vaccines under development and the potential role of vaccination in preventing chikungunya virus infection

Visit mdBriefCase to register.

Target Audience and Goal Statement

This educational activity is intended for an audience of primary care physicians, infectious disease specialists, and public health and preventative medicine specialists.

The goal of this activity is for learners to be better able to identify individuals at risk and how to communicate with potential recipients about the risk/benefit of chikungunya virus vaccines.

Upon completion of this activity, participants will:

• Have increased knowledge regarding the
  • Latest data on the burden of chikungunya disease
  • Data on chikungunya virus vaccines
• Have greater competence related to
  • Identifying who would benefit from the chikungunya vaccine

Visit Medscape to register.

Vaccination remains a very effective method of preventing infectious diseases and represents a relevant contribution to human health. An estimated 3 to 5.5 million deaths are averted each year due to vaccination. This program supports clinicians in discussing the past, present, and future of vaccine innovation. The program provides a foundation on common vaccine types and traditional vaccine development. This is followed by an overview of novel vaccine technologies and their role in known and emerging infectious diseases and diseases not traditionally addressed by vaccination.

Learning objectives:

Upon completion of this continuing education program participants will be better able to:

• Describe common vaccine types and their functionality
• Compare and contrast the benefits and drawbacks of common vaccine types
• Describe novel vaccine technologies and their potential impact on both infectious and non-infectious disease

Visit mdBriefCase to register.

Target Audience and Goal Statement

This activity is intended for a Canadian audience of primary care physicians, obstetricians/gynecologists, oncologists, dentists, otolaryngologists, public and preventive health specialists, nurses, and pharmacists.

The goal of this activity is for learners to be better able to understand the challenges in human papillomavirus (HPV) vaccine uptake and key practical steps and communication triggers that are needed for successful HPV vaccine recommendation or administration.

Upon completion of this activity, participants will:

• Have increased knowledge regarding the Identification of expert recommended practical approaches to increase HPV vaccine uptake such as use of technology and patient engagement (eg, discussing link between virus and cancers)
• Demonstrate greater confidence in their ability to Effectively implement in daily practice communication to unvaccinated people regarding the benefits of HPV vaccination

Visit Medscape to register.

Target Audience and Goal Statement

This activity is intended for primary care physicians, infectious disease specialists, pediatricians, and pharmacists.

The goal of this activity is for learners to be better able to identify optimal strategies to encourage COVID-19 vaccination.

Upon completion of this activity, participants will:

• Have increased knowledge regarding the Distinguishing characteristics among available COVID-19 vaccines
• Have greater competence related to Implementing strategies that address patient hesitancy to vaccination
• Improving vaccine coverage by implementing guideline-recommended vaccine boosters
• Demonstrate greater confidence in their ability to Establish an interprofessional approach to addressing patient concerns related to COVID-19 vaccination

Visit Medscape to register.

Target Audience and Goal Statement

This activity is intended for global (ex-US) allergists and clinical immunologists, hematology/oncology specialists, infectious disease (ID) specialists, nephrologists, pulmonologists, primary care practitioners (PCPs), and transplant surgeons.

The goal of this activity is for learners to be better able to identify immunocompromised people who are at risk for symptomatic COVID-19 infection despite vaccination.

Upon completion of this activity, participants will:

• Have increased knowledge regarding the Risk factors for COVID-19 despite vaccination
• Impact of symptomatic COVID-19 on immunocompromised patients
• Demonstrate greater confidence in their ability to Identify who is at risk for COVID-19 despite vaccination

Visit Medscape to register.